Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a ...
Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...
New Delhi: Accepting the bioequivalence study report for Type 2 Diabetes Mellitus, the Subject Expert Committee (SEC) ...
Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...
Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.